10.1007/s40089-021-00340-2

Investigation of the effect of nanoparticles on platelet storage duration 2010–2020

  • Tahereh Zadeh Mehrizi*1,
  • Peyman Eshghi2,
  1. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR
  2. Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences and Iran Blood Transfusion Organization, Tehran, IR

Published in Issue 2021-05-18

How to Cite

Zadeh Mehrizi, T., & Eshghi, P. (2021). Investigation of the effect of nanoparticles on platelet storage duration 2010–2020. International Nano Letters, 12(1 (March 2022). https://doi.org/10.1007/s40089-021-00340-2
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Abstract In this review study, the effects of different nanoparticles on platelet function and survival, evaluated between 2010 and 2020, have been investigated. The results of these studies showed that among different nanoparticles, the results of functionalized chitosan and anionic dendrimer were more suitable so that chitosan functionalized with salicylic acid can be more effective in increasing platelet survival and improving its function. On the other hand, anionic dendrimers may be appropriate in this regard, but there are very few articles in this field and more studies are needed. Among metallic nanoparticles, it seems that functionalized gold nanoparticles in the proper size and concentration can be more effective than other nanoparticles for increasing survival and improving platelet function. Among non-metallic nanoparticles, single-walled carbon nanotubes functionalized with polymeric nanoparticles are more suitable for increasing the survival and improving platelet function. Overall, the results of this study showed that polymer nanoparticles can have a bright future to increase platelet survival and improve platelet function due to their greater manipulability. Graphic abstract

Keywords

  • Nanoparticles,
  • Platelets,
  • Platelets survival,
  • Platelets storage

References

  1. Palta et al. (2014) Overview of the coagulation system 58(5)
  2. Coêlho et al. (2011) Platelet aggregation and quality control of platelet concentrates produced in the Amazon Blood Bank 33(2) (pp. 110-114)
  3. Ringwald et al. (2014) Residual aggregates in platelet products: what do we know? 106(3) (pp. 209-218)
  4. Yun et al. (2016) Platelet activation: the mechanisms and potential biomarkers https://doi.org/10.1155/2016/9060143
  5. Rondina et al. (2013) Platelets as cellular effectors of inflammation in vascular diseases 112(11) (pp. 1506-1519)
  6. Łukasik et al. (2018) From blood coagulation to innate and adaptive immunity: the role of platelets in the physiology and pathology of autoimmune disorders 38(6) (pp. 959-974)
  7. Xu et al. (2016) Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapies 14(1)
  8. Dobrovolskaia et al. (2012) Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro 9(3) (pp. 382-393)
  9. Koupenova et al. (2018) Circulating platelets as mediators of immunity, inflammation, and thrombosis 122(2) (pp. 337-351)
  10. Ilinskaya and Dobrovolskaia (2016) Nanoparticles and the blood coagulation system (pp. 261-302) World Scientific
  11. Previtali et al. (2011) Risk factors for venous and arterial thrombosis 9(2)
  12. Ilinskaya and Dobrovolskaia (2013) Nanoparticles and the blood coagulation system. Part I: benefits of nanotechnology 8(5) (pp. 773-784)
  13. Fröhlich (2016) Action of nanoparticles on platelet activation and plasmatic coagulation 23(5) (pp. 408-430)
  14. Azeez et al. (2017) Silver nanoparticles (AgNPs) biosynthesized using pod extract of Cola nitida enhances antioxidant activity and phytochemical composition of Amaranthus caudatus Linn 7(1–2) (pp. 59-66)
  15. McCarthy and Jaffer (2011) The role of nanomedicine in the imaging and therapy of thrombosis 6(8) (pp. 1291-1293)
  16. Cicha (2015) Thrombosis: novel nanomedical concepts of diagnosis and treatment
  17. Rizvi and Saleh (2018) Applications of nanoparticle systems in drug delivery technology 26(1) (pp. 64-70)
  18. Wang et al. (2020) Hemostatic nanotechnologies for external and internal hemorrhage management (pp. 4396-4412)
  19. Zielińska et al. (2020) Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology 25(16)
  20. Dashti et al. (2014) Polybutylcyanoacrylate nanoparticles and drugs of the platinum family: Last status 29(3) (pp. 333-338)
  21. Hu et al. (2018) Chitosan-based composite materials for prospective hemostatic applications
  22. Sun et al. (2019) Cytotoxicity-related bioeffects induced by nanoparticles: The role of surface chemistry
  23. Casadidio et al. (2019) Chitin and chitosans: Characteristics, eco-friendly processes, and applications in cosmetic science 17(6)
  24. Mehrizi et al. (2019) Comparative analysis between four model nanoformulations of amphotericin B-chitosan, amphotericin B-dendrimer, betulinic acid-chitosan and betulinic acid-dendrimer for treatment of Leishmania major: Real-time PCR assay plus
  25. Mehrizi et al. (2018) Novel nanosized chitosan-betulinic acid against resistant Leishmania major and first clinical observation of such parasite in kidney (pp. 1-19)
  26. Pourshahrestani et al. (2016) Gallium-containing mesoporous bioactive glass with potent hemostatic activity and antibacterial efficacy (pp. 71-86)
  27. Gu et al. (2010) The performance of a fly-larva shell-derived chitosan sponge as an absorbable surgical hemostatic agent (pp. 1270-1277)
  28. Wang et al. (2019) Biological effects of chitosan-based dressing on hemostasis mechanism 11(11)
  29. Sagnella and Mai-Ngam (2005) Chitosan based surfactant polymers designed to improve blood compatibility on biomaterials 42(2) (pp. 147-155)
  30. He et al. (2013) Positive charge of chitosan retards blood coagulation on chitosan films (pp. 1032-1045)
  31. Wang et al. (2020) Recent advances in chitosan-based metal nanocomposites for wound healing applications https://doi.org/10.1155/2020/3827912
  32. Lord et al. (2011) The modulation of platelet adhesion and activation by chitosan through plasma and extracellular matrix proteins 32(28) (pp. 6655-6662)
  33. Chung et al. (2014) Adenosine diphosphate-decorated chitosan nanoparticles shorten blood clotting times, influencing the structures and varying the mechanical properties of the clots
  34. Ramtoola et al. (2011) Investigation of the interaction of biodegradable micro-and nanoparticulate drug delivery systems with platelets 63(1) (pp. 26-32)
  35. Shelma and Sharma (2011) Development of lauroyl sulfated chitosan for enhancing hemocompatibility of chitosan (pp. 561-570)
  36. Xiong et al. (2011) Selective carboxypropionylation of chitosan: synthesis, characterization, blood compatibility, and degradation (pp. 1217-1223)
  37. Jiang et al. (2012) Stable nanomicelles based on chitosan derivative: In vitro antiplatelet aggregation and adhesion properties 88(1) (pp. 232-238)
  38. Bender et al. (2012) Hemocompatibility of poly (ɛ-caprolactone) lipid-core nanocapsules stabilized with polysorbate 80-lecithin and uncoated or coated with chitosan 426(1–2) (pp. 271-279)
  39. Periayah et al. (2013) In vitro capacity of different grades of chitosan derivatives to induce platelet adhesion and aggregation (pp. 244-249)
  40. Nadesh et al. (2013) Hematotoxicological analysis of surface-modified and-unmodified chitosan nanoparticles 101(10) (pp. 2957-2966)
  41. Jesus et al. (2020) Chitosan Nanoparticles: Shedding Light on Immunotoxicity and Hemocompatibility
  42. Gopalakrishnan et al. (2014) Ellagic acid encapsulated chitosan nanoparticles as anti-hemorrhagic agent (pp. 215-221)
  43. Kim et al. (2016) Nanoencapsulation of red ginseng extracts using chitosan with polyglutamic acid or fucoidan for improving antithrombotic activities (pp. 4765-4771)
  44. Roeven et al. (2019) Design, synthesis, and characterization of fully zwitterionic, functionalized dendrimers 4(2) (pp. 3000-3011)
  45. Hsu et al. (2017) Dendrimer-based nanocarriers: A versatile platform for drug delivery 9(1)
  46. Greish et al. (2012) Size and surface charge significantly influence the toxicity of silica and dendritic nanoparticles (pp. 713-723)
  47. Jones et al. (2012) Cationic PAMAM dendrimers disrupt key platelet functions 9(6) (pp. 1599-1611)
  48. Jones et al. (2012) Cationic PAMAM dendrimers aggressively initiate blood clot formation 6(11) (pp. 9900-9910)
  49. Watala et al. (2016) How do the full-generation poly (amido) amine (PAMAM) dendrimers activate blood platelets? Activation of circulating platelets and formation of “fibrinogen aggregates” in the presence of polycations (pp. 247-261)
  50. Fu et al. (2014) Effects of poly (amidoamine) dendrimers on the structure and function of key blood components 29(2) (pp. 165-179)
  51. Markowicz-Piasecka et al. (2014) Studies towards biocompatibility of PAMAM dendrimers–overall hemostasis potential and integrity of the human aortic endothelial barrier 473(1–2) (pp. 158-169)
  52. Enciso et al. (2016) Nanoparticle effects on human platelets in vitro: A comparison between PAMAM and triazine dendrimers 21(4)
  53. Aisina et al. (2020) Influence cationic and anionic PAMAM dendrimers of low generation on selected hemostatic parameters in vitro
  54. Durán-Lara et al. (2013) PAMAM dendrimer derivatives as a potential drug for antithrombotic therapy (pp. 601-608)
  55. Liu et al. (2015) Dual-functionalized poly (amidoamine) dendrimers with poly (ethylene glycol) conjugation and thiolation improved blood compatibility 67(11) (pp. 1492-1502)
  56. Li et al. (2019) Comprehensive investigation of in vitro hemocompatibility of surface modified polyamidoamine nanocarrier (pp. 267-279)
  57. de Castro et al. (2010) Functionalized congeners of P2Y1 receptor antagonists: 2-Alkynyl (N)-methanocarba 2′-deoxyadenosine 3′, 5′-bisphosphate analogues and conjugation to a polyamidoamine (PAMAM) dendrimer carrier 21(7) (pp. 1190-1205)
  58. Nabavizadeh et al. (2016) Evaluation of nanocarrier targeted drug delivery of Capecitabine-PAMAM dendrimer complex in a mice colorectal cancer model (pp. 485-493)
  59. Guan et al. (2015) Low cytotoxicity fluorescent PAMAM dendrimer as gene carriers for monitoring the delivery of siRNA 17(9)
  60. Ziemba et al. (2011) In vivo toxicity of poly (propyleneimine) dendrimers 99(2) (pp. 261-268)
  61. Ziemba et al. (2012) Influence of fourth generation poly (propyleneimine) dendrimers on blood cells (pp. 2870-2880)
  62. Franiak-Pietryga et al. (2012) Nanoparticles: A novel approach to chronic lymphocytic leukemia treatment? 120(21) (pp. 4601-4601)
  63. Franiak-Pietryga et al. (2013) The influence of maltotriose-modified poly (propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: dense shell G4 PPI (pp. 2490-2501)
  64. Mehrizi et al. (2018) Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major
  65. Mirzaei et al. (2012) Novel nanosized Gd3+-ALGD-G2-C595: in vivo dual selective MUC-1 positive tumor molecular MR imaging and therapeutic agent 3(7) (pp. 147-152)
  66. Zadeh Mehrizi et al. (2018) In vivo therapeutic effects of four synthesized antileishmanial nanodrugs in the treatment of Leishmaniasis https://doi.org/10.5812/archcid.80314
  67. Akbarzadeh et al. (2013) Liposome: classification, preparation, and applications 8(1)
  68. Beltrán-Gracia et al. (2019) Nanomedicine review: clinical developments in liposomal applications 10(1)
  69. Zhang et al. (2017) Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis
  70. Okamura et al. (2010) Release abilities of adenosine diphosphate from phospholipid vesicles with different membrane properties and their hemostatic effects as a platelet substitute (pp. 373-379)
  71. Srinivasan et al. (2010) In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes (pp. 1004-1015)
  72. Vaidya et al. (2011) Development and characterization of site specific target sensitive liposomes for the delivery of thrombolytic agents (pp. 254-261)
  73. Kuznetsova et al. (2012) Hemocompatibility of liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the lipid bilayer (pp. 394-400)
  74. Lateef et al. (2018) (pp. 243-277) Springer
  75. Mody et al. (2010) Introduction to metallic nanoparticles 2(4)
  76. Deb et al. (2012) Surface tunability of nanoparticles in modulating platelet functions 48(1) (pp. 36-44)
  77. Hante et al. (2019) Effect on platelet function of metal-based nanoparticles developed for medical applications https://doi.org/10.3389/fcvm.2019.00139
  78. Love et al. (2012) Development of screening assays for nanoparticle toxicity assessment in human blood: preliminary studies with charged Au nanoparticles 7(9) (pp. 1355-1364)
  79. Deb et al. (2011) Multistability in platelets and their response to gold nanoparticles 7(4) (pp. 376-384)
  80. Lee et al. (2018) Blood biochemical and hematological study after subacute intravenous injection of gold and silver nanoparticles and coadministered gold and silver nanoparticles of similar sizes https://doi.org/10.1155/2018/8460910
  81. Santos-Martinez et al. (2014) Pegylation increases platelet biocompatibility of gold nanoparticles 10(6) (pp. 1004-1015)
  82. He et al. (2018) The effects of gold nanoparticles on the human blood functions 46(sup2) (pp. 720-726)
  83. Tian et al. (2014) Antithrombotic functions of small molecule-capped gold nanoparticles 6(15) (pp. 8543-8550)
  84. Uchiyama et al. (2014) In vivo and in vitro toxicity and anti-inflammatory properties of gold nanoparticle bioconjugates to the vascular system 142(2) (pp. 497-507)
  85. Hecold et al. (2017) The effect of PEI and PVP-stabilized gold nanoparticles on equine platelets activation: potential application in equine regenerative medicine https://doi.org/10.1155/2017/8706921
  86. Marycz et al. (2015) Application of gold nanoparticles of different concentrations to improve the therapeutic potential of autologous conditioned serum: potential implications for equine regenerative medicine https://doi.org/10.1155/2015/521207
  87. Aseychev et al. (2013) Effect of gold nanoparticles coated with plasma components on ADP-induced platelet aggregation 155(5) (pp. 685-688)
  88. Shrivastava et al. (2009) Characterization of antiplatelet properties of silver nanoparticles 3(6) (pp. 1357-1364)
  89. Bandyopadhyay et al. (2012) Silver nano particles prevent platelet adhesion on immobilized fibrinogen 27(2) (pp. 164-170)
  90. Krajewski et al. (2013) Hemocompatibility evaluation of different silver nanoparticle concentrations employing a modified Chandler-loop in vitro assay on human blood 9(7) (pp. 7460-7468)
  91. Haberl et al. (2015) Effects of acute systemic administration of TiO2, ZnO, SiO2, and Ag nanoparticles on hemodynamics, hemostasis and leukocyte recruitment 9(8) (pp. 963-971)
  92. Laloy et al. (2014) Impact of silver nanoparticles on haemolysis, platelet function and coagulation
  93. Milić et al. (2020) Effect of differently coated silver nanoparticles on hemostasis https://doi.org/10.1080/09537104.2020.1792432
  94. Hajtuch et al. (2019) Effects of functionalized silver nanoparticles on aggregation of human blood platelets
  95. Martínez-Gutierrez et al. (2012) Antibacterial activity, inflammatory response, coagulation and cytotoxicity effects of silver nanoparticles 8(3) (pp. 328-336)
  96. Ragaseema et al. (2012) The antithrombotic and antimicrobial properties of PEG-protected silver nanoparticle coated surfaces 33(11) (pp. 3083-3092)
  97. Asghar et al. (2020) Antibacterial, anticoagulant and cytotoxic evaluation of biocompatible nanocomposite of chitosan loaded green synthesized bioinspired silver nanoparticles (pp. 934-943)
  98. Lateef et al. (2016) Anti-candida, anti-coagulant and thrombolytic activities of biosynthesized silver nanoparticles using cell-free extract of Bacillus safensis LAU 13 51(10) (pp. 1406-1412)
  99. Vinayagam et al. (2017) Evaluation of the anticoagulant and catalytic activities of the Bridelia retusa fruit extract-functionalized silver nanoparticles 28(5) (pp. 2919-2932)
  100. Kumar et al. (2012) Green synthesis of silver nanoparticles with Zingiber officinale extract and study of its blood compatibility 2(3) (pp. 144-152)
  101. Krishnaraj and Berchmans (2013) In vitro antiplatelet activity of silver nanoparticles synthesized using the microorganism Gluconobacter roseus: an AFM-based study 3(23) (pp. 8953-8959)
  102. Fedel (2020) Hemocompatibility of Carbon Nanostructures 6(1)
  103. Maiti et al. (2019) Carbon-based nanomaterials for biomedical applications: A recent study
  104. Lee et al. (2020) Carbon dot nanoparticles exert inhibitory effects on human platelets and reduce mortality in mice with acute pulmonary thromboembolism 10(7)
  105. Jović et al. (2020) The puzzling potential of carbon nanomaterials: General properties, application, and toxicity 10(8)
  106. Gaffney et al. (2015) Blood biocompatibility of surface-bound multi-walled carbon nanotubes 11(1) (pp. 39-46)
  107. Koh et al. (2009) A novel nanostructured poly (lactic-co-glycolic-acid)–multi-walled carbon nanotube composite for blood-contacting applications: Thrombogenicity studies 5(9) (pp. 3411-3422)
  108. Takahashi et al. (2009) Improved blood biocompatibility of composite film of chitosan/carbon nanotubes complex 23(1) (pp. 64-71)
  109. Burke et al. (2011) Determinants of the thrombogenic potential of multiwalled carbon nanotubes 32(26) (pp. 5970-5978)
  110. Meng et al. (2012) Effects of long and short carboxylated or aminated multiwalled carbon nanotubes on blood coagulation 7(7)
  111. De Paoli Lacerda et al. (2011) Carbon nanotubes activate store-operated calcium entry in human blood platelets 5(7) (pp. 5808-5813)
  112. Guidetti et al. (2012) Nanoparticles induce platelet activation in vitro through stimulation of canonical signalling pathways 8(8) (pp. 1329-1336)
  113. Bihari et al. (2010) Single-walled carbon nanotubes activate platelets and accelerate thrombus formation in the microcirculation 269(2–3) (pp. 148-154)
  114. Vakhrusheva et al. (2013) Albumin reduces thrombogenic potential of single-walled carbon nanotubes 221(2) (pp. 137-145)
  115. Holzer et al. (2014) Carbon-based nanomaterials accelerate arteriolar thrombus formation in the murine microcirculation independently of their shape 34(11) (pp. 1167-1176)
  116. Bussy et al. (2013) Hemotoxicity of carbon nanotubes 65(15) (pp. 2127-2134)
  117. McKay et al. (1971) Mechanism of thrombosis of the microcirculation 63(2)
  118. Kumari et al. (2014) Nanodiamonds activate blood platelets and induce thromboembolism 9(3) (pp. 427-440)
  119. Zhao et al. (2017) Novel carbon quantum dots from egg yolk oil and their haemostatic effects 7(1) (pp. 1-8)
  120. Liu et al. (2018) Novel Phellodendri Cortex (Huang Bo)-derived carbon dots and their hemostatic effect 13(4) (pp. 391-405)
  121. Abed et al. (2019) Streptokinase loading fabrication magnetic nanoparticle supported with tannic acid as a modified thrombolytic agent (pp. 34-47)
  122. Andrievsky et al. (2010) The acceleration of blood plasma clot lysis in the presence of hydrated C60 fullerene nanostructures in super-small concentration 18(3) (pp. 303-311)
  123. Xia et al. (2018) Small size fullerenol nanoparticles inhibit thrombosis and blood coagulation through inhibiting activities of thrombin and FXa 14(3) (pp. 929-939)
  124. Mona et al. (2013) Adsorption of human blood plasma on nanodiamond and its influence on activated partial thromboplastin time (pp. 73-77)
  125. Sasidharan et al. (2012) Hemocompatibility and macrophage response of pristine and functionalized graphene 8(8) (pp. 1251-1263)
  126. Singh et al. (2011) Thrombus inducing property of atomically thin graphene oxide sheets 5(6) (pp. 4987-4996)
  127. Loh and Lim (2015) Molecular hemocompatibility of graphene oxide and its implication for antithrombotic applications 11(38) (pp. 5105-5117)
  128. Park et al. (2011) The effect of particle size on the cytotoxicity, inflammation, developmental toxicity and genotoxicity of silver nanoparticles 32(36) (pp. 9810-9817)
  129. Yen et al. (2009) Cytotoxicity and immunological response of gold and silver nanoparticles of different sizes 5(13) (pp. 1553-1561)
  130. Stensberg et al. (2011) Toxicological studies on silver nanoparticles: challenges and opportunities in assessment, monitoring and imaging 6(5) (pp. 879-898)
  131. Tao et al. (2019) Albumin conjugates and assemblies as versatile bio-functional additives and carriers for biomedical applications 7(3) (pp. 357-367)
  132. Hong et al. (2006) Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability 17(3) (pp. 728-734)
  133. Lee and Larson (2006) Molecular dynamics simulations of PAMAM dendrimer-induced pore formation in DPPC bilayers with a coarse-grained model 110(37) (pp. 18204-18211)
  134. Mecke et al. (2005) Lipid bilayer disruption by polycationic polymers: The roles of size and chemical functional group 21(23) (pp. 10348-10354)
  135. Dobrovolskaia et al. (2012) Dendrimer-induced leukocyte procoagulant activity depends on particle size and surface charge 7(2) (pp. 245-256)
  136. Zbinden et al. (1989) Assessment of thrombogenic potential of liposomes 54(3) (pp. 273-280)